Microneedles Drug Delivery Systems for Treatment of Cancer: A Recent Update
Aravindram Attiguppe Seetharam,
Hani Choudhry,
Muhammed A. Bakhrebah,
Wesam H. Abdulaal,
Maram Suresh Gupta,
Syed Mohd Danish Rizvi,
Qamre Alam,
Siddaramaiah,
Devegowda Vishakante Gowda,
Afrasim Moin
Affiliations
Aravindram Attiguppe Seetharam
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSSAHER), Sri Shivarathreeshwara Nagar, Mysore 570015, India
Hani Choudhry
Department of Biochemistry, Cancer Metabolism & Epigenetic Unit, Faculty of Science, Cancer & Mutagenesis Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia
Muhammed A. Bakhrebah
Life Science & Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia
Wesam H. Abdulaal
Department of Biochemistry, Cancer Metabolism & Epigenetic Unit, Faculty of Science, Cancer & Mutagenesis Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia
Maram Suresh Gupta
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSSAHER), Sri Shivarathreeshwara Nagar, Mysore 570015, India
Syed Mohd Danish Rizvi
Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail 81481, Saudi Arabia
Qamre Alam
Medical Genomics Research Department, King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh 11426, Saudi Arabia
Siddaramaiah
Department of Polymer Science and Technology, Sri Jayachamarajendra College of Engineering, Mysore 570016, India
Devegowda Vishakante Gowda
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSSAHER), Sri Shivarathreeshwara Nagar, Mysore 570015, India
Afrasim Moin
Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail 81481, Saudi Arabia
Microneedles (MNs) are tiny needle like structures used in drug delivery through layers of the skin. They are non-invasive and are associated with significantly less or no pain at the site of administration to the skin. MNs are excellent in delivering both small and large molecules to the subjects in need thereof. There exist several strategies for drug delivery using MNs, wherein each strategy has its pros and cons. Research in this domain lead to product development and commercialization for clinical use. Additionally, several MN-based products are undergoing clinical trials to evaluate its safety, efficacy, and tolerability. The present review begins by providing bird’s-eye view about the general characteristics of MNs followed by providing recent updates in the treatment of cancer using MNs. Particularly, we provide an overview of various aspects namely: anti-cancerous MNs that work based on sensor technology, MNs for treatment of breast cancer, skin carcinoma, prostate cancer, and MNs fabricated by additive manufacturing or 3 dimensional printing for treatment of cancer. Further, the review also provides limitations, safety concerns, and latest updates about the clinical trials on MNs for the treatment of cancer. Furthermore, we also provide a regulatory overview from the “United States Food and Drug Administration” about MNs.
